Drug Type Monoclonal antibody |
Synonyms Revdofilimab, PR-1628103 |
Target |
Mechanism OX40 agonists(Tumor necrosis factor receptor superfamily member 4 agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Head and Neck Neoplasms | Phase 1 | US | 22 Jan 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 1 | US | 22 Jan 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 1 | FR | 22 Jan 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 1 | DE | 22 Jan 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 1 | IL | 22 Jan 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 1 | NL | 22 Jan 2020 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 1 | ES | 22 Jan 2020 | |
Metastatic Solid Tumor | Phase 1 | US | 21 May 2019 | |
Metastatic Solid Tumor | Phase 1 | AU | 21 May 2019 | |
Metastatic Solid Tumor | Phase 1 | FR | 21 May 2019 |
Phase 1 | Metastatic Solid Tumor | Advanced Malignant Solid Neoplasm | Triple Negative Breast Cancer ... OX40 positive View more | - | lnazzqjcch(bmptciihqo) = thvgyrccrj yywwyedrbt (qlpbqatymn ) | - | 01 Nov 2019 | ||
NCT03071757 (ESMO2018) Manual | Phase 1 | 38 | ozdzjjvaee(vbsamgazcz) = qaouqglqmu ewasvmtavx (ldvibsifqu ) View more | Positive | 20 Oct 2018 |